Since the principle of the Activating KRAS Detection Chip is to detect the expression customer review of multiple downstream genes from KRAS, it could reveal the integral situation of activating KRAS instead of detecting the status from a single marker, which may be undetectable because of detection limitations, and in this way also overcome the heterogeneity issue. Our recently developed membrane array based multi marker assay can detect activating KRAS mutations in the circulating RNA in the peripheral blood of patients with various malignancies, including colorectal cancer, achieving considerable sensitivity, specificity, and accur acy when compared to the direct sequencing of tumor tissues. The results of the current study demonstrate that WEnCA is a sensitive and convenient technique for detecting activated KRAS from the peripheral blood of NSCLC and CRC cancer patients.

Inhibitors,Modulators,Libraries In fact, the sensitivity of WEnCA reached 92. 13% and the specificity reached 94. 68% in this study, and the similar results which the sen sitivity, specificity, Inhibitors,Modulators,Libraries and accuracy were all above 92% in pre vious studies using WEnCA platform. Although the Next Generation Sequencing is a rapidly developed high throughput technique that improves the sensitivity Inhibitors,Modulators,Libraries and reduces the cost of Sanger sequencing, the difficulty in tumor tissue specimen collection still cause the limitation for this method. Even NGS can be applied to RNA sequencing using blood sample, the data analysis and inter pretation is quiet complicated especially compared with WEnCA platform which is easy to interpret and only needs basic calculation.

Moreover, the overall cost of NGS is higher than membrane based WEnCA plat form currently. The identification of activated KRAS status could be extremely useful in selecting feasible CRC patients for cetuximab therapy, allowing some patients Inhibitors,Modulators,Libraries to avoid un necessary treatment. In the present study, the relapse rate was only 1751 in stage III CRC patients with negative chip results who received cetuximab ther apy. on the other hand, the rate was 75% among patients with positive chip results. There were prominent associ ations between the chip results and relapse status, and these associations could therefore be used as a pre cetuximab therapy predictor for clinical outcomes of stage III CRC. This finding Inhibitors,Modulators,Libraries could be useful in the future for identifying HTC individual risk and developing alternative therapeutic strategies. Conclusions This present study indicated that a panel of molecular markers could be applied, in conjunction with our con structed membrane array method with weighted calcu lation, to detect activating KRAS status from circulating RNA in the peripheral blood of NSCLC and CRC patients.